For our assays, we used NLR unmodified Raji cells expressing CD19 and CD20 (Raji) and NLG CD19-deficient Raji cells (CD19 KO Raji) to evaluate the ability of armed iNK-CD64/16A cells to switch tumor antigen targeting. This evidence concerns the gene CD19 and neoplasm.